BofA lowered the firm’s price target on Encompass Health (EHC) to $150 from $160 and keeps a Buy rating on the shares. Q1 EBITDA beat by 3% despite weaker volumes, notes the analyst, who raised estimates following the report but trimmed the firm’s target to reflect lower peer group multiples.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Lifts 2026 Outlook After Strong Q1
- Encompass Health (EHC) Q1 Earnings Cheat Sheet
- Encompass Health: Maintaining a Buy on Intact Long‑Term Earnings Power Despite Near‑Term Volume Noise
- Encompass Health: Medicare Rate Proposal Reinforces Pricing Outlook and Supports Buy Rating
- Encompass Health to build 40-bed inpatient rehabilitation hospital in Delaware